Buscar en
Vacunas (English Edition)
Toda la web
Inicio Vacunas (English Edition) Factors associated with the non-development of immunogenicity in vaccinated adul...
Journal Information
Vol. 22. Issue 3.
Pages 158-166 (September - December 2021)
Share
Share
Download PDF
More article options
Visits
1
Vol. 22. Issue 3.
Pages 158-166 (September - December 2021)
Original article
Factors associated with the non-development of immunogenicity in vaccinated adults against the hepatitis B virus
Factores asociados al no desarrollo de inmunogenicidad en adultos vacunados contra el virus de la hepatitis B
Visits
1
S. Mendívil-Tuchia de Taia,b, C.A. Arana-Calderónc,d, W. Aguirre-Quispeb,e,
Corresponding author
wilfor.aguirre.q@upch.pe

Corresponding author.
a Hospital Central de la Fuerza Aérea del Perú, Lima, Peru
b Universidad Nacional Mayor de San Marcos, Lima, Peru
c Hospital I Pacasmayo – Essalud, La Libertad, Pacasmayo, Peru
d Universidad Nacional de Trujillo, La Libertad, Trujillo, Peru
e Instituto Nacional de Ciencias Neurológicas, Lima, Peru
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (2)
Table 1. General characteristics according to seroprotection condition.
Table 2. Risk factors associated with non-protection against HBV according to binary logistic regression models.
Show moreShow less
Additional material (1)
Abstract
Objectives

to analyze the factors associated with the non-development of immunogenicity in the adult population vaccinated against HBV.

Materials and Methods

A case-control study was performed in a population of patients vaccinated against HBV, who were titrated to antibodies against HBV surface antigen between the years 2015 and 2016. Adults (>18 years) vaccinated against HBV, titrated to anti-HBs < 10 mIU/mL, and who did not present chronic hepatitis B or previous history of HBV infection were defined as cases. The controls were defined with the same characteristics of the cases, the only difference being a titre of anti-HBs ≥ 10 mIU/mL. The factors analyzed were age, sex, number of doses, and some comorbidities such as HIV infection, type 2 diabetes mellitus, and chronic kidney disease on hemodialysis. A bivariate analysis was performed using the Mann-Whitney Chi2 and U tests, as well as a multivariate analysis using binary logistic regression to generate a predictive model.

Results

The cohort of patients with anti-HBs titers was composed of 205 participants, which included 39 cases and 166 controls (power: 91%, significance of 0.05). The bivariate analysis showed that the variables age (OR 3.19, P = .005), number of vaccine doses (OR 4.82, P = .001), hemodialysis CKD (OR 8.85, P = .001), Diabetes mellitus 2(OR 4.38, P = .001), and the time from onset of vaccination (OR 0.36, P = .006), were associated with non-development of seroprotection against HBV. Likewise, age groups >40 years and >60 years were highly significant in this analysis, OR 3.19 and OR 8.93, respectively. In the multivariate analysis, only age as a numerical variable (OR: 1.05) and number of doses (OR: 2.74), after being adjusted by the other variables, were the only ones that explained the non-development of seroprotection in adults. The final logistic model with the variables indicated explains in 74% the non-seroprotection.

Conclusions

Age and number of doses are the only associated variables able to predict with high certainty the non-seroprotective vaccination against HBV.

Keywords:
Hepatitis B virus
Vaccine immunogenicity
Antibodies
Hepatitis B vaccines
Resumen
Objetivos

Analizar los factores asociados al no desarrollo de seroprotección en población adulta vacunada contra VHB.

Materiales y Métodos

Se realizó un estudio de casos y controles en una muestra de pacientes adultos vacunados contra VHB, a quienes se les midió títulos de anticuerpos contra el antígeno de superficie para VHB (anti-HBs) entre los años 2015 y 2016. Se definió como caso a los adultos (≥18 años) vacunados contra el VHB, con titulación de anti-HBs < 10 mUI/mL, y que no haya presentado hepatitis B crónica o antecedente de infección resuelta por el VHB. Los controles fueron definidos con las mismas características de los casos, siendo la única diferencia una titulación de anti-HBs ≥ 10 mUI/mL. Los factores analizados fueron la edad, el sexo, el número de dosis y algunas comorbilidades como infección por VIH, Diabetes mellitus tipo 2 y enfermedad renal crónica en hemodiálisis. Se realizó un análisis bivariante mediante las pruebas de Chi2 y U de Mann-Whitney, así como un análisis multivariado mediante regresión logística binaria para generar un modelo predictivo.

Resultados

La cohorte de pacientes con titulación de anti-HBs estuvo formada por 205 participantes, la cual incluyó 39 casos y 166 controles (potencia: 91%, significancia α de 0.05). El análisis bivariante mostró que las variables edad (OR 3.19; P = .005), número de dosis vacunal (OR 4.82; P = .001), ERC en hemodiálisis (OR 8.85; P = .001), Diabetes mellitus (OR4.38; P = .001), y el tiempo desde el inicio de la vacunación (OR 0.36; P = .006), se asociaron al no desarrollo de seroprotección contra el VHB. Asimismo, los grupos de edad ≥40 años y ≥60 años, resultaron altamente significativos en este análisis, OR 3.19 y OR 8.93 respectivamente. En el análisis multivariado, solo la edad como variable numérica (OR: 1.05) y el número de dosis (OR: 2.74), tras ser ajustadas por las demás variables, fueron las únicas que explicaron el no desarrollo de seroprotección en adultos. El modelo logístico final con las variables señaladas explica en un 74% la no seroprotección.

Conclusiones

La edad y el número de dosis son las únicas variables asociadas capaces de predecir con alta certeza la no seroprotección vacunal contra el VHB.

Palabras clave:
Virus de la hepatitis B
Inmunogenicidad vacunal
Anticuerpos contra la hepatitis B
Vacunas contra hepatitis B

Article

These are the options to access the full texts of the publication Vacunas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Vacunas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos